Generic Name and Formulations:
Salsalate 500mg, 750mg; scored tabs.
Various generic manufacturers
Indications for Salsalate:
Rheumatoid arthritis. Osteoarthritis.
3g daily in divided doses.
Varicella or influenza in teenagers. 3rd trimester pregnancy. Aspirin allergy. Coronary artery bypass graft surgery.
Advanced renal disease: not recommended. Impaired renal or hepatic function. Hypertension. Heart failure. Edema. Bleeding disorders. Monitor blood, liver, renal function with chronic use. Peptic ulcer. Gastritis. Diabetes. Elderly. Debilitated. Pregnancy (Cat.C). Nursing mothers: not recommended.
PABA may increase serum levels. May potentiate anticoagulants, hypoglycemics, methotrexate. Urinary alkalinizers, antacids, corticosteroids may increase excretion. May antagonize uricosurics and spironolactone.
Salicylism, tinnitus, nausea, dyspepsia, GI bleed, hearing loss, rash (discontinue if occurs). See literature re: risk of cardiovascular events.
Formerly known under the brand names Disalcid, Salflex.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|